Health Catalyst (NASDAQ:HCAT) Director Sells $128,151.99 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) Director Julie Larson-Green sold 47,997 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $2.67, for a total value of $128,151.99. Following the completion of the transaction, the director owned 73,573 shares in the company, valued at $196,439.91. This represents a 39.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Health Catalyst Trading Down 1.1%

NASDAQ HCAT traded down $0.03 during trading on Tuesday, reaching $2.61. 493,261 shares of the stock traded hands, compared to its average volume of 704,965. Health Catalyst, Inc. has a fifty-two week low of $2.02 and a fifty-two week high of $8.52. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.46. The firm has a market cap of $184.61 million, a price-to-earnings ratio of -1.64 and a beta of 1.72. The stock’s 50-day moving average price is $2.83 and its 200 day moving average price is $3.30.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Monday, November 10th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.05 by $0.01. Health Catalyst had a negative return on equity of 6.67% and a negative net margin of 34.05%.The business had revenue of $76.32 million for the quarter, compared to the consensus estimate of $75.05 million. Analysts predict that Health Catalyst, Inc. will post -0.33 EPS for the current year.

Wall Street Analyst Weigh In

HCAT has been the subject of a number of research reports. Piper Sandler cut Health Catalyst from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $8.00 to $4.00 in a research note on Wednesday, August 27th. UBS Group reiterated an “outperform” rating on shares of Health Catalyst in a report on Tuesday, November 11th. Citigroup lowered their price objective on shares of Health Catalyst from $3.50 to $3.25 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Evercore ISI dropped their price objective on shares of Health Catalyst from $4.00 to $3.00 and set an “in-line” rating on the stock in a report on Wednesday, October 8th. Finally, Canaccord Genuity Group reduced their target price on shares of Health Catalyst from $9.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, August 29th. Five equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $4.36.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of HCAT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Health Catalyst by 7.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company’s stock worth $163,000 after purchasing an additional 2,624 shares in the last quarter. Campbell & CO Investment Adviser LLC grew its stake in shares of Health Catalyst by 9.7% in the second quarter. Campbell & CO Investment Adviser LLC now owns 43,051 shares of the company’s stock valued at $162,000 after buying an additional 3,808 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Health Catalyst by 19.6% during the second quarter. The Manufacturers Life Insurance Company now owns 26,491 shares of the company’s stock worth $100,000 after buying an additional 4,341 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Health Catalyst by 71.7% during the third quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company’s stock worth $47,000 after buying an additional 6,832 shares during the last quarter. Finally, Probity Advisors Inc. raised its position in Health Catalyst by 20.5% during the third quarter. Probity Advisors Inc. now owns 45,161 shares of the company’s stock worth $129,000 after acquiring an additional 7,671 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.